Validation of a new prognostic staging system for hepatocellular carcinoma: A comparison of the biomarker-combined Japan integrated staging score, the conventional Japan integrated staging score and the BALAD score

Oncology

Volumn 75, Issue SUPPL. 1, 2008, Pages 83-90

  Kitai, Satoshi ^a   Kudo, Masatoshi ^a   Minami, Yasunori ^a   Haji, Seiji ^a   Osaki, Yukio ^b   Oka, Hiroko ^c   Seki, Toshihito ^d   Kasugai, Hiroshi ^e   Sasaki, Yo ^e   Matsunaga, Takashi ^e  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b OSAKA RED CROSS HOSPITAL   (Japan)

^c OSAKA CITY GENERAL HOSPITAL   (Japan)

^d KANSAI MEDICAL UNIVERSITY   (Japan)

^e OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

Author keywords

Fetoprotein; BALAD score; Biomarker combined Japan integrated staging score; Des carboxy prothrombin; Japan integrated staging score; Lens culinaris agglutinin reactive fetoprotein fraction

Indexed keywords

ALPHA FETOPROTEIN; DECARBOXYPROTHROMBIN; LENS CULINARIS AGGLUTININ REACTIVE ALPHA FETOPROTEIN; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; BALAD SCORE; BIOMARKER COMBINED JAPANA INTEGRATED STAGING SCORE; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; COMPARATIVE STUDY; CONFERENCE PAPER; CONTROLLED STUDY; CONVENTIONAL JAPAN INTEGRATED STAGING SCORE; DIAGNOSTIC ACCURACY; DISEASE MARKER; FEMALE; HUMAN; INTERMETHOD COMPARISON; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; SCORING SYSTEM; SURVIVAL RATE; VALIDATION STUDY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; JAPAN; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 58149087266     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000173428     Document Type: Conference Paper

References (41)

1. Oka H, Tamori A, Kuroki T, et al: Prospective study of alpha-fetoprotein in cirrhotic patients monitored for development of hepatocellular carcinoma. Hepatology 1994;19:61-66.
2. Ikeda K, Saitoh S, Koida I, et al: A multivariate analysis of risk factors for hepatocellular carcinogenesis: a prospective observation of 795 patients with viral and alcoholic cirrhosis. Hepatology 1993;18:47-53.
3. Tsukuma H, Hiyama T, Tanaka S, et al: Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 1993;328:1797-1801
4. Aoyagi Y, Isokawa O, Suda T, Watanabe M, Suzuki Y, Asakura H: Fucosylation index of alpha-fetoprotein as a possible prognostic indicator in patients with hepatocellular carcinoma. Cancer 1998;83:2076-2082.
5. Santon C, Taylor R, Wallin R: Processing of prothrombin in the secretory pathway. Biochem J 1991;277:59-65.
6. Taketa K, Sekiya C, Namiki N, et al: Lectin-reactive profiles of alpha-fetoprotein characterizing hepatocellular carcinoma and related conditions. Gastroenterology 1990;99:508-518.
7. Liebman HA, Furie BC, Tong MJ, et al: Des-gamma-carboxy (abnormal) prothrombin as a serum marker of patients with hepatocellular carcinoma. N Engl J Med 1984;310:1427-1431.
8. Fujiyama S, Tanaka M, Maeda S, et al: Tumor markers in early diagnosis, follow-up and management of patients with hepatocellular carcinoma. Oncology 2002;62:S57-S63.
9. Kudo M, Okanoue T: Management of hepatocellular carcinoma in Japan: consensus-based clinical practice manual proposed by the Japan Society of Hepatology. Oncology 2007;72:S2-S15.
10. Di Bisceglie AM, Hoofnagle JH: Elevations in serum alpha-fetoprotein levels in patients with chronic hepatitis B. Cancer 1989;64:2117-2120.
11. Yamashita F, Tanaka M, Satomura S, Tanikawa K: Prognostic significance of lens culinaris agglutinin A-reactive alpha-fetoprotein in small hepatocellular carcinomas. Gastroenterology 1996;111:996-1001.
12. Kobayashi M, Kuroiwa T, Suda T, Tamura Y, Kawai H, Igarashi M, Fukuhara Y, Aoyagi Y: Fucosylated fraction of alpha-fetoprotein, L3, as a useful prognostic factor in patients with hepatocellular carcinoma with special reference to low concentrations of serum alpha-fetoprotein. Hepatol Res 2007;37:914-922.
13. Suehiro T, Sugimachi K, Matsumata T, et al: Protein induced by vitamin K absence or antagonist II as a prognostic marker in hepatocellular carcinoma. Comparison with alpha-fetoprotein. Cancer 1994;73:2464-2471.
14. Koike Y, Shiratori Y, Sato S, et al: Des-gamma-carboxy prothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinoma: a prospective analysis of 227 patients. Cancer 2001;91:561-569.
15. Toyoda H, Kumada T, Kiriyama S, Sone Y, Tanikawa M, Hisanaga Y, Yamaguchi A, Isogai M, Kaneoka Y, Washizu J: Prognostic significance of simultaneous measurement of three tumor markers in patients with hepatocellular carcinoma. Clin Gastroenterol Hepatol 2006;4:111-117.
16. Tateishi R, Shiina S, Yoshida H, Teratani T, Obi S, Yamasaki N, Yoshida H, Akamatsu M, Kawabe T, Omata M: Prediction of recurrence of hepatocellular carcinoma after curative ablation using three tumor markers. Hepatology 2006;44:1518-1527.
17. Kudo M, Chung H, Osaki Y: Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score). J Gastroenterol 2003;38:207-215.
18. Liver Cancer Study Group of Japan: The General Rules for the Clinical and Pathological Study of Primary Liver Cancer (in Japanese), ed 4. Tokyo, Kanehara, 2000.
19. Liver Cancer Study Group of Japan: The General Rules for the Clinical and Pathological Study of Primary Liver Cancer, ed 2. Tokyo, Kanehara, 2003.
20. Kudo M, Chung H, Haji S, Osaki Y, Oka H, Seki T, Kasugai H, Sasaki Y, Matsunaga T: Validation of a new prognostic staging system for hepatocellular carcinoma: the JIS score compared with the CLIP score. Hepatology 2004;40:1396-1405.
21. Toyoda H, Kumada T, Kiriyama S, et al: Comparison of usefulness of three staging systems for hepatocellular carcinoma (CLIP, BCLC, JIS) in Japan. Am J Gastroenterol 2005;100:1764-1771.
22. Chung H, Kudo M, Takahashi S, Hagiwara S, Sakaguchi Y, Inoue T, Minami Y, Ueshima K, Fukunaga T, Matsunaga T: Comparison of three current staging systems for hepatocellular carcinoma: Japan integrated staging score, new Barcelona Clinic Liver Cancer staging classification, and Tokyo score. J Gastroenterol Hepatol 2008;23:445-452.
23. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology 1998;28:751-755.
24. Chevret S, Trinchet JC, Mathieu D, Rached AA, Beaugrand M, Chastang C: A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. Groupe d'Etude et de Traitement du Carcinome Hépatocellulaire. J Hepatol 1999;31:133-141.
25. Leung TW, Tang AM, Zee B, Lau WY, Lai PB, Leung KL, Lau JT, Yu SC, Johnson PJ: Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: a study based on 926 patients. Cancer 2002;94:1760-1769.
26. Toyoda H, Kumada T, Osaki Y, Oka H, Urano F, Kudo M, Matsunaga T: Staging hepatocellular carcinoma by a novel scoring system (BALAD score) based on serum markers. Clin Gastroenterol Hepatol 2006;4:1528-1536.
27. Kitai S, Kudo M, Minami Y, Ueshima K, Chung H, Hagiwara S, Inoue T, Ishikawa E, Takahashi S, Asakuma Y, Haji S, Osaki Y, Oka H, Seki T, Kasugai H, Sasaki Y, Matsunaga T: A new prognostic staging system for hepatocellular carcinoma: value of the biomarker combined Japan integrated staging score. Intervirology 2008;51(suppl 1):86-94.
28. Torzilli G, Minagawa M, Takayama T, Inoue K, Hui AM, Kubota K, et al: Accurate preoperative evaluation of liver mass lesions without fine-needle biopsy. Hepatology 1999;30:889-893.
29. Bruix J, Sherman M;Practice Guidelines Committee, American Association for the Study of Liver Diseases: Management of hepatocellular carcinoma. Hepatology 2005;42:1208-1236.
30. Kaplan EL, Meier P: Nonparametric estimation for incomplete observation. J Am Stat Assoc 1958;53:457-481.
31. Petro R, Pike MC: Conservation of the approximation for (0-E2)/E in the log rank test for survival data on tumor incidence data. Biometrics 1973;29:579-584.
32. Akaike H: A new look at statistical model identification. IEEE Trans Autom Control 1974;AC-19:716-722.
33. Llovet JM, Bru C, Bruix J: Prognosis of hepatocellular carcinoma: BCLC staging classification. Semin Liver Dis 1999;19:329-337.
34. Llovet JM, Bruix J, Fuster J, Castells A, Garcia-Valdecasas JC, Grande L, Franca A, et al: Liver transplantation for small hepatocellular carcinoma: the tumor-node metastasis classification does not have prognostic power. Hepatology 1998;27:1572-1577.
35. Lui WY, Chiu ST, Chiu JH, Loong CC, Chau GY, King KL, Hsia CY, et al: Evaluation of a simplified staging system for prognosis of hepatocellular carcinoma. J Formos Med Assoc 1999;4:248-253.
36. Calvet X, Bruix J, Bru C, Gines P, Vilana R, Sole M, Ayuso MC, et al: Natural history of hepatocellular carcinoma in Spain. Five years' experience in 249 cases. J Hepatol 1990;10:311-317.
37. Yamanaka N, Okamoto E, Toyosaka A, Mitunobu M, Fujihara S, Kato T, Fujimoto J, et al: Prognostic factors after hepatectomy for hepatocellular carcinomas. Cancer 1990;65:1104-1110.
38. Kasahara A, Hayashi N, Fusamoto H, et al: Clinical evaluation of plasma des-gamma-carboxy prothrombin as a marker protein of hepatocellular carcinoma in patients with tumors of various sizes. Dig Dis Sci 1993;38:2170-2176.
39. Hamamura K, Shiratori Y, Shiina S, et al: Unique clinical characteristics of patients with hepatocellular carcinoma who present with high plasma des-gamma-carboxy prothrombin and low serum alpha-fetoprotein. Cancer 2000;88:1557-1564.
40. Kudo M: New sonographic techniques for the diagnosis and treatment of hepatocellular carcinoma. Hepatol Res 2007;37:S193-S199.
41. Hatanaka K, Kudo M, Minami Y, Ueda T, Tatsumi C, Kitai S, Takahashi S, Inoue T, Hagiwara S, Chung H, Ueshima K, Maekawa K: Differential diagnosis of hepatic tumors: value of contrast-enhanced harmonic sonography using the newly developed contrast agent, Sonazoid. Intervirology 2008;51:S61-S69.